Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Sponsor: Incyte Corporation
Summary
This study will be conducted to determine the safety, tolerability, dose-limiting toxicity (DLT)s, and maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE)s of INCA036978 administered as monotherapy and in combination with a standard disease-directed therapy.
Official title: A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
218
Start Date
2026-03-29
Completion Date
2030-05-24
Last Updated
2026-03-19
Healthy Volunteers
No
Conditions
Interventions
INCA036978
INCA036978 will be administered at protocol defined dose.
Standard disease-directed therapy
A standard disease-directed therapy will be administered according to Prescribing Information/SmPC.
Locations (45)
University of Alabama At Birmingham
Birmingham, Alabama, United States
City of Hope-Lennar Foundation Cancer Center
Irvine, California, United States
Usc Norris Comprehensive Cancer Center
Los Angeles, California, United States
UCLA Medical Hematology & Oncology
Los Angeles, California, United States
Yale Cancer Center
New Haven, Connecticut, United States
University of Miami
Miami, Florida, United States
Moffitt Cancer Center
Tampa, Florida, United States
Winship Cancer Institute of Emory University
Atlanta, Georgia, United States
John Hopkins Hospital
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Washington University School of Medicine
St Louis, Missouri, United States
Mount Sinai School of Medicine
New York, New York, United States
Weill Cornell Medicine
New York, New York, United States
University of North Carolina At Chapel Hill
Chapel Hill, North Carolina, United States
Levine Cancer Institute
Charlotte, North Carolina, United States
Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy
Durham, North Carolina, United States
Cleveland Clinic
Cleveland, Ohio, United States
Ohio State University
Columbus, Ohio, United States
Tristar Bmt/Tcto
Nashville, Tennessee, United States
University of Texas M. D. Anderson Cancer Center
Houston, Texas, United States
Huntsman Cancer Institute
Salt Lake City, Utah, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Concord General Repatriation Hospital
Concord, New South Wales, Australia
Royal North Shore Hospital
St Leonards, New South Wales, Australia
Icon Cancer Centre
Auchenflower, Queensland, Australia
Epworth Health Care
East Melbourne, Victoria, Australia
Linear Clinical Research
Nedlands, Western Australia, Australia
Centre Hospitalier Universitaire (Chu) de Liege
Liège, Belgium
AZ DELTA
Roeselare, Belgium
Institut Bergonie
Bordeaux, France
Hospital Saint Louis
Paris, France
University Medical Center Rwth Aachen
Aachen, Germany
Charite Universitaetsmedizin Berlin - Campus Charite Mitte
Berlin, Germany
Universitatklinikum Freiburg
Freiburg im Breisgau, Germany
Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
Mainz, Germany
Aou Policlinico S. Orsola-Malpighi
Bologna, Italy
Fondazione Irccs Ca' Granda - Ospedale Maggiore Policlinico
Milan, Italy
A. Gemelli University Hospital, Catholic University of the Sacred Heart
Roma, Italy
Azienda Sanitaria Universitaria Friuli Centrale Asu Fc
Udine, Italy
Hospital Universitari Germans Trias I Pujol
Badalona, Spain
Hospital Universitario de Gran Canaria Dr. Negrin
Las Palmas de Gran Canaria, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Guy'S Hospital - Guy'S & St Thomas' Nhs Foundation Trust
London, United Kingdom
Nottingham University Hospitals
Nottingham, United Kingdom
University of Oxford
Oxford, United Kingdom